Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response
Open accessAbstract
Background: Major depressive disorder is a debilitating illness, which is most commonly treated with antidepressant drugs. As the majority of patients do not respond on their first trial, there is great interest in identifying biological factors that indicate the most appropriate treatment for each patient. Studies suggest that microRNA represent excellent biomarkers to predict antidepressant response. Methods: We investigated the expression of miR-1202, miR-135a, and miR-16 in peripheral blood from 2 cohorts of depressed patients who received 8 weeks of antidepressant therapy. Expression was quantified at baseline and after treatment, and its relationship to treatment response and depressive symptoms was assessed. Results: In both cohorts, responders displayed lower baseline miR-1202 levels compared with nonresponders, which increased following treatment. Conclusions: Ultimately, our results support the involvement of microRNA in antidepressant response and suggest that quantification of their levels in peripheral samples represents a valid approach to informing treatment decisions.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
miR-1202 has consistently been reported to be associated with treatment response to antidepressants using the candidate approach.
“In addition, we found that miR-1202, which has consistently been reported to be associated with treatment response to antidepressants using the candidate approach [46,50], was also correlated with treatment response based on our genome-wide approach.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414 · see citing works
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879 · see citing works
MiR-16 Targets the Serotonin Transporter: A New Facet for Adaptive Responses to Antidepressants
Baudry, A., Mouillet-Richard, S., Schneider, B., Launay, J.-M., & Kellermann, O. (2010) · Science · doi:10.1126/science.1193692 · Cited by 480 · see citing works
Issler, O., Haramati, S., Paul, E. D., Maeno, H., Navon, I., Zwang, R., Gil, S., Mayberg, H. S., Dunlop, B. W., Menke, A., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.05.042 · Cited by 318 · see citing works
Lopez, J. P., Lim, R., Cruceanu, C., Crapper, L., Fasano, C., Labonte, B., Maussion, G., Yang, J. P., Yerko, V., Vigneault, E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3582 · Cited by 308 · see citing works
Self-citationSex differences in glutamate receptor gene expression in major depression and suicide
Gray, A. L., Hyde, T. M., Deep-Soboslay, A., Kleinman, J. E., & Sodhi, M. S. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.91 · Cited by 250 · see citing works
Bai, M., Zhu, X., Zhang, Y., Zhang, S., Zhang, L., Xue, L., Yi, J., Yao, S., & Zhang, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046921 · Cited by 195 · see citing works
Raphe-mediated signals control the hippocampal response to SRI antidepressants via miR-16
Launay, J., Mouillet‐Richard, S., Baudry, A., Pietri, M., & Kellermann, O. (2011) · Translational Psychiatry · doi:10.1038/tp.2011.54 · Cited by 118 · see citing works
Song, M.-F., Dong, J., Wang, Y.-W., He, J., Ju, X., Zhang, L., Zhang, Y., Shi, J., & Lv, Y.-Y. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.02.022 · Cited by 111 · see citing works
Mannironi, C., Camon, J., Vito, F. D., Biundo, A., Stefano, M. E. D., Persiconi, I., Bozzoni, I., Fragapane, P., Mele, A., & Presutti, C. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073385 · Cited by 77 · see citing works
Pathogenetic and therapeutic applications of microRNAs in major depressive disorder
Dwivedi, Y. (2015) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.02.003 · Cited by 70 · see citing works
Chronic Academic Stress Increases a Group of microRNAs in Peripheral Blood
Honda, M., Kuwano, Y., Katsuura‐Kamano, S., Kamezaki, Y., Fujita, K., Akaike, Y., Kano, S., Nishida, K., Masuda, K., & Rokutan, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075960 · Cited by 59 · see citing works
Lopez, J. P., Pereira, F., Richard-Devantoy, S., Berlim, M., Chachamovich, E., Fiori, L. M., Niola, P., Turecki, G., & Jollant, F. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.9 · Cited by 50 · see citing works
Self-citationŻurawek, D., Kuśmider, M., Faron‐Górecka, A., Gruca, P., Pabian, P., Solich, J., Kolasa, M., Papp, M., & Dziedzicka‐Wasylewska, M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-0107-9 · Cited by 46 · see citing works
Żurawek, D., Kuśmider, M., Faron‐Górecka, A., Gruca, P., Pabian, P., Kolasa, M., Solich, J., Szafran‐Pilch, K., Papp, M., & Dziedzicka‐Wasylewska, M. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.11.013 · Cited by 38 · see citing works
Jiang, Q. L., & Ahmed, S. (2009) · Annals of General Psychiatry · doi:10.1186/1744-859x-8-4 · Cited by 34 · see citing works
Belzeaux-R, R., Lin, C., Ding, Y., Bergon, A., Ibrahim, E. C., Turecki, G., Tseng, G. C., & Sibille, E. L. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.07.009 · Cited by 31 · see citing works
Self-citationDadkhah, T., Rahimi-Aliabadi, S., Jamshidi, J., Ghaedi, H., Taghavi, S., Shokraeian, P., Akhavan-Niaki, H., Tafakhori, A., Ohadi, M., & Darvish, H. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.008 · Cited by 26 · see citing works
Cruceanu, C., López, J. P., Tsai, W. J., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.138 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Biomarkers in Psychiatry: Concept, Definition, Types and Relevance to the Clinical Reality
García-Gutiérrez, M. S., Navarrete, F., Sala, F., Gasparyan, A., Austrich-Olivares, A., & Manzanares, J. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.00432 · Cited by 331 · see citing works
Blood biomarkers and treatment response in major depression
Mora, C., Zonca, V., Riva, M. A., & Cattaneo, A. (2018) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2018.1470927 · Cited by 107 · see citing works
Lopez, J. P., Kos, A., & Turecki, G. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000379 · Cited by 108 · see citing works
Self-citationGruzdev, S. K., Yakovlev, A. A., Druzhkova, T. A., Guekht, A. B., & Gulyaeva, N. V. (2019) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-019-00684-6 · Cited by 75 · see citing works
MicroRNAs as critical biomarkers of major depressive disorder: a comprehensive perspective
Ortega, M. A., Alvarez-Mon, M. A., García-Montero, C., Fraile-Martinez, O., Lahera, G., Monserrat, J., Muñoz-Merida, L., Mora, F., Rodríguez-Jiménez, R., Fernandez-Rojo, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9111659 · Cited by 57 · see citing works
Segaran, R. C., Chan, L. Y., Wang, H., Sethi, G., & Tang, F. R. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200121122910 · Cited by 42 · see citing works
miRNAs in depression vulnerability and resilience: novel targets for preventive strategies
Lopizzo, N., Zonca, V., Cattane, N., Pariante, C. M., & Cattaneo, A. (2019) · Journal of Neural Transmission · doi:10.1007/s00702-019-02048-2 · Cited by 37 · see citing works
Kato, M., Ogata, H., Tahara, H., Shimamoto, A., Takekita, Y., Koshikawa, Y., Nishida, K., Nonen, S., Higasa, K., & Kinoshita, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073873 · Cited by 23 · see citing works
Ni, L., Zhu, Y., Lv, L., Zhang, R., Xie, S., & Zhang, X. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.04.126 · Cited by 3 · see citing works
- Authors
- Fiori, L. M., Lopez, J. P., Richard-Devantoy, S., Berlim, M., Chachamovich, E., Jollant, F., Foster, J., Rotzinger, S., Kennedy, S. H., & Turecki, G.
- Affiliations
- University Health Network (CA)
- Corresponding author
- Turecki, Gustavo
- ORCID
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-06-06
- Volume
- 20
- Issue
- 8
- Pages
- 619-623
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC5570004
- OpenAlex
- W2614538492
- Cited by
- 71
- References
- 19
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 9 · 2023: 8 · 2022: 9 · 2021: 11 · 2020: 8 · 2019: 10 · 2018: 3 · 2017: 3
- FWCI
- 4.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Ontario Brain Institute
- Fondation Brain Canada
- Sunovion
- Government of Ontario
- Servier
- H. Lundbeck A/S
- National Institutes of Health
- St. Jude Medical
- Allergan
- Canadian Institutes of Health Research (MOP119430, MOP11260, MOP93775, MOP119429, FDN148374)
- Fonds de Recherche du Québec - Santé
- National Institute on Drug Abuse (R01DA033684)
- Topics
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- major depressive disorder, antidepressant response, microRNA, miR-135a, miR-16, biomarkers, peripheral blood, treatment response prediction, depressive symptoms
- MeSH terms
- Clinical Decision-Making, Duloxetine Hydrochloride, Desvenlafaxine Succinate, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Humans, Psychiatric Status Rating Scales, ROC Curve, Citalopram, Biomarkers, Treatment Outcome, MicroRNAs, Depressive Disorder, Treatment-Resistant
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
